Idera Pharmaceuticals Inc. [NASDAQ: IDRA] stock went on a downward path that fall over -62.00% on Friday, amounting to a one-week price decrease of less than -59.34%. The company report on March 19, 2021 that Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma.
– Objective Response Rate Endpoint Not Met –.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR). Idera is evaluating its next steps regarding continuation of the trial toward its overall survival (OS) endpoint, which includes evaluating the full data set when it is available. The Company also plans to continue its ILLUMINATE-206 Phase 2 study of tilsotolimod in combination with ipilimumab and nivolumab in patients with microsatellite stable colorectal cancer (MSS-CRC).
Over the last 12 months, IDRA stock rose by 63.64%. The average equity rating for IDRA stock is currently 1.80, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $220.20 million, with 36.29 million shares outstanding and 25.52 million shares in the current float. Compared to the average trading volume of 759.12K shares, IDRA stock reached a trading volume of 49731311 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Idera Pharmaceuticals Inc. [IDRA]:
Wedbush have made an estimate for Idera Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 19, 2021. The new note on the price target was released on March 19, 2021, representing the official price target for Idera Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Idera Pharmaceuticals Inc. is set at 0.72
IDRA Stock Performance Analysis:
Idera Pharmaceuticals Inc. [IDRA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -59.34. With this latest performance, IDRA shares dropped by -59.18% in over the last four-week period, additionally sinking by -24.14% over the last 6 months – not to mention a rise of 63.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IDRA stock in for the last two-week period is set at 26.81, with the RSI for the last a single of trading hit 21.65, and the three-weeks RSI is set at 30.88 for Idera Pharmaceuticals Inc. [IDRA]. The present Moving Average for the last 50 days of trading for this stock 4.9146, while it was recorded at 4.3420 for the last single week of trading, and 3.2187 for the last 200 days.
Insight into Idera Pharmaceuticals Inc. Fundamentals:
Reflecting on the efficiency of the workforce at the company, Idera Pharmaceuticals Inc. [IDRA] managed to generate an average of -$3,520,687 per employee.Idera Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.90 and a Current Ratio set at 5.90.
IDRA Stock EPS
With the latest financial reports released by the company, Idera Pharmaceuticals Inc. posted 0.22/share EPS, while the average EPS was predicted by analysts to be reported at -0.41/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 153.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IDRA.
Idera Pharmaceuticals Inc. [IDRA] Insider Position Details
There are presently around $19 million, or 22.60% of IDRA stock, in the hands of institutional investors. The top three institutional holders of IDRA stocks are: BAKER BROS. ADVISORS LP with ownership of 4,608,786, which is approximately 0% of the company’s market cap and around 1.40% of the total institutional ownership; VANGUARD GROUP INC, holding 1,021,296 shares of the stock with an approximate value of $2.02 million in IDRA stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $2.01 million in IDRA stock with ownership of nearly 5.577% of the company’s market capitalization.
Positions in Idera Pharmaceuticals Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 30 institutional holders increased their position in Idera Pharmaceuticals Inc. [NASDAQ:IDRA] by around 1,273,856 shares. Additionally, 14 investors decreased positions by around 570,678 shares, while 13 investors held positions by with 7,693,573 shares. The mentioned changes placed institutional holdings at 9,538,107 shares, according to the latest SEC report filing. IDRA stock had 15 new institutional investments in for a total of 933,377 shares, while 3 institutional investors sold positions of 21,401 shares during the same period.